Treatment of rheumatoid arthritis through inhibition of tumour necrosis factor using infliximab or etanercept;Behandeling van reumatoïde artritis door blokkade van tumornecrosisfactor met infliximab of etanercept

Nederlands Tijdschrift voor Geneeskunde

Volumn 145, Issue 39, 2001, Pages 1880-1885

  Tijhuis, G J ^a   Van De Putte, L B ^a   Breedveld, F C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; ETANERCEPT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CLINICAL TRIAL; HUMAN; NONHUMAN; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOGLOBULIN G; METHOTREXATE; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035968617     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Survival and cause of death in rheumatoid arthritis: A 25-year prospective follow-up
2. Review of UK data on the rheumatic diseases - 2. Rheumatoid arthritis
3. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis
4. Efficacy of low-dose methotrexate in rheumatoid arthritis
5. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies
6. Second-line drug therapy for rheumatoid arthritis
7. Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis
8. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
9. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
10. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor-alpha
11. p55 and p75 tumor necrosis factor receptors are expressed and mediate common functions in synovial fibroblasts and other fibroblasts
12. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha
13. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cAa) versus placebo in rheumatoid arthritis
14. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis
15. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
16. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
17. Infliximab and methotrexate in the treatment of rheumatoid arthritis
18. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis
19. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (P75)-Fc fusion protein
20. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
21. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexatc
22. Long-term use of etanercept in patients with DMARD-refractory rheumatoid arthritis
23. Long-term safety and efficacy of combination therapy with methotrexate (MTX) and etanercept (Enbrel)
24. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
25. Etanercept in children with polyarticular juvenile rheumatoid arthritis